FDA May Allow Trials for Algernon’s Psychedelic DMT

Canada-based Algernon announced its clinical program in January based in part on a preclinical study published last year in Experimental Neurology by researchers from Semmelweis University, which showed DMT can promote neurogenesis and neuroplasticity in a rat model of brain ischemia.

Field Trip Health’s New Psilocybin Research Facility Probes the Secrets of Shrooms

“Clinical studies on psilocybin and other plant-based psychedelic compounds have shown that they have great potential to produce profoundly positive changes in individuals, particularly those struggling from serious mental health conditions like anorexia, depression, and PTSD,”

By |2021-02-28T22:21:33-08:00February 28, 2021|Magic Mushrooms, Studies|0 Comments

Forget Cannabis – Psilocybin May be the Next Big Opportunity

Psygen is a Calgary-based company specializing in the synthetic manufacture of psychedelic medicines. The company provides non-exclusive access to psychedelic drug products for clinical research, therapeutic applications and is a leading supplier for the emerging commercial market.

MDMA The New Way to Treat PTSD

How likely is the FDA to approve MDMA to treat PTSD? It is, after all, a psychedelic drug in Schedule I, which defines it as highly dangerous with no therapeutic value. Apparently, back in 2017, the FDA identified MDMA as a ‘breakthrough therapy’ for PTSD.

By |2021-02-25T20:10:08-08:00February 24, 2021|Articles & News, MDMA, Psychedelic Therapy, Studies|0 Comments

Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

Science in Action has confirmed that it has received ethics approval for an in vivo non-GLP toxicology study of N, N Dimethyltryptamine (DMT) (the "Study"). Both Entheon and Science in Action have applied for requisite permits in order to export, receive and research DMT drug product.

By |2021-02-22T23:05:28-08:00February 22, 2021|DMT, Psychedelic News, Studies|0 Comments

Psychedelics And Schizophrenia: What’s The Link?

A 2018 study provides further clarity on the relationship between psychedelics and schizophrenia. Both break down the barriers between self and other. We know LSD does this by quieting parts of the brain related to ego we’re back to the influence on the 5-HT2A receptors again. (We’re unclear why this occurs in schizophrenics.)

By |2021-02-21T23:40:28-08:00February 21, 2021|Articles & News, LSD, Studies|0 Comments

MindMed to Study Potential ‘Off Switch’ for LSD

Psychedelic medicine biotech firm MindMed has announced it has begun a study for a “neutralizer” technology that could shorten and stop the effects of an LSD trip during therapy, paving the way for an “emergency shut-off switch” for psychedelic-assisted therapy.

By |2021-02-20T01:14:27-08:00February 20, 2021|Articles & News, LSD, Studies|0 Comments

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants. No unexpected adverse events were observed, and psychosocial functioning improved across the cohort.

By |2021-02-20T00:31:37-08:00February 20, 2021|MDMA, Studies|0 Comments

Numinus Announces Milestones in Compassionate Access Trial for MDMA Assisted Therapy in Collaboration with MAPS Public Benefit Corporation

Numinus Announces Milestones in Compassionate Access Trial for MDMA [...]

By |2021-02-19T00:26:58-08:00February 19, 2021|Articles & News, MDMA, Studies|0 Comments

Can LSD Cure Our Pandemic Anxiety? MindMed is Spending Big to Find Out

MindMed is one of those companies. The Toronto-based firm is led by JR Rahn, a former Uber executive whose cocaine addiction led him to try psychedelics as a treatment—an experience he credits with saving his life. Rahn believes drugs like LSD could hold the key to helping the millions of people who have been driven to despair by the pandemic.

By |2021-02-18T22:16:23-08:00February 18, 2021|Articles & News, LSD, Studies|0 Comments
Go to Top